APA (7th ed.) Citation

Martin-Broto, J., Valverde, C., Hindi, N., Vincenzi, B., Martinez-Trufero, J., Grignani, G., . . . Moura, D. S. (2023). REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Molecular Cancer, 22(1), 1. https://doi.org/10.1186/s12943-023-01832-9

Chicago Style (17th ed.) Citation

Martin-Broto, Javier, et al. "REGISTRI: Regorafenib in First-line of KIT/PDGFRA Wild Type Metastatic GIST: A Collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II Trial." Molecular Cancer 22, no. 1 (2023): 1. https://doi.org/10.1186/s12943-023-01832-9.

MLA (9th ed.) Citation

Martin-Broto, Javier, et al. "REGISTRI: Regorafenib in First-line of KIT/PDGFRA Wild Type Metastatic GIST: A Collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II Trial." Molecular Cancer, vol. 22, no. 1, 2023, p. 1, https://doi.org/10.1186/s12943-023-01832-9.